I agree with virtually all of your post, though I actually Am a fan of LP. I haven't met her. But I've been in enough microcaps, and early biotechs to know that she's pulled off a major coup here if she gets this to a successful completion, and that's what looks to me is likely to happen here.
As for people being xenophobic or sinophobic about their support of the Huawei sale leaseback, but not necessarily as a China partner, I am extremely familiar with China, am connected to businesses there that are some of the biggest in China, and I still prefer a different route. Huawei, given it's troubles, would be an unfortunate domestic partner in China, and doing business in China is not for tiny companies like this... loss of intellectual property is virtually a given. That's not xenophobia, that's a fact, and large companies know it and are very careful what they do and bring to China. That's not about xenophobia, as I said, go to Japan or Korea first, find a reliable partner that is well experienced and already manufactures these kinds of products and already has the capacity, not a phone / telecommunications company, and then work with regional partners eventually on China. China also simply does not have a well-developed drug development sector, and there is no reason for a tiny company with a potential blockbuster like this to subject itself to being an experiment, with political and intellectual property implications. That's about going after the best markets first, with the most reliable and technologically savvy partners first, and going after a less developed market, and avoiding troubled partners. It's not sinophobia or xenophobia. Every single day, all everything I do, and have done, for quite some time, involves international commercial business. My focus is on expediting success and eliminating risk, and not just a funky pop, success, but a success that bring the treatment to as many patients as possible, in as many markets as possible, with as successful a monetization as possible, without over charging.
Don't misjudge people who disagree with you on strategy. I also don't like people assuming things that are not true and posting them all over. It tends to undermine the confidence of investors and they often misattribute such posts to management. The fact of a sale-leaseback was not enough to suggest Huawai was buying NWBO prior to top line, nor would it have made sense. And as a local partner, I sitll think it would be a bad move, made purely on China hype, rather than the reality on the ground. It could bring attention initially, but slow progress and ultimately undermine the company's success, for the reasons I indicated here and above.
News 
Market Data 
Discover 
